Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MK-3795 in advanced ccRCC
NCT02293980Phase 1Active, not recruiting
- Sponsor
- Merck & Co.
- Start
- Nov 2014
- Primary completion
- Jan 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of PT-2385 in clear cell renal cell carcinoma (ccRCC) (3 arms), sponsored by Merck & Co. Primary endpoints: Maximum Tolerated Dose at 4 weeks and Recommended Phase 2 Dose at 4 weeks. Started Nov 2014; status: active, not recruiting.
02
Drugs
PT-2385
03
Conditions
clear cell renal cell carcinoma (ccRCC)
Beyond the preview
Go deeper on NCT02293980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02293980.